Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer-Reference-Cited by-同舟云学术

Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer

Published:2015-08-26 Issue:302 Volume:7 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Garcia-Murillas Isaac¹,Schiavon Gaia¹²,Weigelt Britta³,Ng Charlotte³,Hrebien Sarah¹,Cutts Rosalind J.¹,Cheang Maggie⁴,Osin Peter²,Nerurkar Ashutosh²,Kozarewa Iwanka¹,Garrido Javier Armisen¹,Dowsett Mitch¹²,Reis-Filho Jorge S.³,Smith Ian E.²,Turner Nicholas C.¹²

Affiliation:

1. Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, Fulham Road, London SW3 6JB, UK.

2. Breast Unit, Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK.

3. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

4. Institute of Cancer Research Clinical Trials and Statistics Unit, The Institute of Cancer Research, 15 Cotswold Road, Surrey SM2 5NG, UK.

Abstract

Noninvasive mutation tracking in plasma can detect circulating tumor DNA arising from residual micrometastatic disease and thus identify patients at high risk of recurrence.

Funder

Breast Cancer Research Foundation

Cancer Research UK

Mary-Jean Mitchell Green Foundation

Cridlan Trust

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference35 articles.

1. Global cancer statistics

2. US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status